货号:A189348
同义名:
BMP Inhibitor III
LDN-212854是一种骨形态发生蛋白 (BMP) 抑制剂,能够有效抑制 ALK2,IC50 为 1.3 nM,同时也抑制 ALK1 (IC50: 2.40 nM)。该化合物可用于研究进行性骨化纤维发育不良及相关癌症(如肝细胞癌 HCC)。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 靶点 |
|
| 描述 | The bone morphogenetic protein (BMP) signaling pathway has essential functions in development, homeostasis, and in the normal and pathophysiologic remodeling of tissues. BMPs initiate their signaling events through an interaction of their type I and type II receptors, both of which are transmembrane serine/threonine kinases. Seven type I receptors (a.k.a. activin receptor-like receptors; ALK1 to ALK7) and four type II receptors have been identified in mice and humans[3].. LDN-212854 is a selective and potent inhibitor of the BMP type I receptor kinases, with the IC50 values of 1.3 nM, 2.4 nM, 85.8 nM, 2133 nM, 9276 nM for ALK2, ALK1, ALK3, ALK4 and ALK5, respectively. LDN-212854 (IC50=37 nM) displayed low nanomolar potency in blocking the phosphorylation of SMAD1/5/8 induced by BMP7 (20 ng/mL, 30 min) in BMPR2−/− pulmonary vascular smooth muscle cells. ALK2Q207D transgenic mice model was used to evaluate the efficacy of LDN-212854 in vivo. After pretreating pericytes with 570nM LDN-212854 for 1 day, the osteoblast differentiation of pericytes from FOR hiPSCs was partly inhibited. Treatment with LDN-212854 on the dose of 6 mg/kg twice daily for 4 weeks can prevent the formation of heterotopic bone and preserved limb range of motion with minimal or no impairment in the majority of mice[4]. |
| 作用机制 | LDN-212854 binds type I BMP receptor at the ATP-binding pocket. The pendant 5-quinoline group of LDN-212854 is predicted to form an alternative water-mediated hydrogen bond to the catalytic lysine (K235) of ALK2[5]. |
| Concentration | Treated Time | Description | References | |
| Mesenchymal cells | 750 nM | 12, 24, 48, 72, and 96 hr | Evaluate the effect of LDN-212854 on mesenchymal cell proliferation, results show LDN-212854 significantly reduces cell proliferation | Mol Ther. 2017 Aug 2;25(8):1974-1987. |
| Bone marrow mononuclear cells (BMMs) | 1 μM | 5 days | LDN-212854 inhibits SMAD1/5/9 phosphorylation, thereby inhibiting osteoclastogenesis in caAcvr1 mutant cells. | J Biol Chem. 2019 Nov 22;294(47):17818-17836. |
| Primary rat OPCs | 0.18 μM | 3 days | To evaluate the effect of LDN-212854 on OPC differentiation in the presence of fibrinogen, results showed that LDN-212854 restored mature oligodendrocyte differentiation and reduced GFAP+ astrocyte formation. | Brain. 2021 Sep 4;144(8):2291-2301. |
| HSG cells | 0.1, 1.0 or 10 nM | 4 days | To investigate the effect of LDN-212854 on BMP6-induced loss of cell membrane water permeability. Results showed that LDN-212854 inhibited BMP6-induced RVD loss in a dose-dependent manner. | Sci Rep. 2020 Feb 19;10(1):2967. |
| HSG cells | 10 or 60 nM | 24 hours | To investigate the effect of LDN-212854 on BMP6-induced SMAD1/5/8 phosphorylation. Results showed that 60 nM LDN-212854 significantly reduced BMP6-induced SMAD1/5/8 phosphorylation. | Sci Rep. 2020 Feb 19;10(1):2967. |
| C2C12 cells | 500 nM | 3 days | To test the inhibitory effect of LDN-212854 on BMP2-induced alkaline phosphatase (ALP) activity, results showed that LDN-212854 significantly suppressed ALP activity. | Stem Cell Res Ther. 2024 Apr 5;15(1):98. |
| Human mesenchymal stromal cells (MSCs) | 500 nM | 28 days | To test the effect of LDN-212854 on MSC chondrogenesis in vitro, results showed that LDN-212854 mildly inhibited chondrogenesis but had limited effects on hypertrophy markers. | Stem Cell Res Ther. 2024 Apr 5;15(1):98. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Ntv-a;p53fl/fl mice | Intraperitoneally | 6 mg/kg | Twice daily for 5 consecutive days (in vitro); twice a day until euthanasia endpoints were met (in vivo survival study) | To evaluate the effect of LDN212854 on tumor growth and survival, results showed that LDN212854 significantly prolonged survival. | Nat Commun. 2019 Mar 4;10(1):1023. |
| Mice | Burn/tenotomy model | Intraperitoneal injection | 6 mg/kg | Daily for 6 weeks | Evaluate the effect of LDN-212854 on trauma-induced heterotopic ossification, results show LDN-212854 significantly reduces heterotopic ossification volume | Mol Ther. 2017 Aug 2;25(8):1974-1987. |
| Mouse | Acvr1[R206H]FlEx/+ conditional knock-in mice | Subcutaneous injection | 3 mg/kg | Twice daily for 4 weeks | LDN-212854 effectively suppressed spontaneous joint/ligament HO and injury-triggered intramuscular HO in Acvr1R206H mice, demonstrating selective ACVR1 inhibition abrogates cell-autonomous effects of mutant receptors in tendon and muscle progenitors. | Sci Transl Med. 2016 Nov 23;8(366):366ra163 |
| Mice | C57BL/6.NOD-Aec1Aec2 mouse model | Intraperitoneal injection | 2.5 mg/kg | Once daily for 24 days | To investigate the effect of LDN-212854 on the restoration of salivary gland function in C57BL/6.NOD-Aec1Aec2 mice. Results showed that LDN-212854 treatment significantly increased salivary flow rate and reduced phosphorylation of SMAD1/5/8 and expression of ID3. | Sci Rep. 2020 Feb 19;10(1):2967. |
| NCG mice | HCC xenograft model | Intraperitoneal injection | 6 mg/kg | Twice daily for 10-14 days | LDN-212854 significantly suppressed HCC tumor growth and induced global RNA m6A methylation | Int J Mol Sci. 2024 Jan 12;25(2):981. |
| NOD/SCID mice | HCC xenograft model | Intraperitoneal injection | 6 mg/kg | Twice daily for 10-14 days | Inhibited HCC tumor growth and angiogenesis | Int J Mol Sci. 2022 Jan 27;23(3):1475. |
| Dose | Mice: 6 mg/kg[1] (i.p.) |
| Administration | i.p. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.46mL 0.49mL 0.25mL |
12.30mL 2.46mL 1.23mL |
24.60mL 4.92mL 2.46mL |
|
| CAS号 | 1432597-26-6 |
| 分子式 | C25H22N6 |
| 分子量 | 406.48 |
| SMILES Code | C12=C(C3=C4N=CC(C5=CC=C(N6CCNCC6)C=C5)=CN4N=C3)C=CC=C1N=CC=C2 |
| MDL No. | MFCD28099808 |
| 别名 | BMP Inhibitor III |
| 运输 | 蓝冰 |
| InChI Key | BBDGBGOVJPEFBT-UHFFFAOYSA-N |
| Pubchem ID | 60182388 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 30 mg/mL(73.8 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1